| Donald J Faith, MD | |
|
3415 Millers Run Rd, Cecil, PA 15321-1403 | |
| (724) 873-7414 | |
| (724) 872-7421 |
| Full Name | Donald J Faith |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 3415 Millers Run Rd, Cecil, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063481257 | NPI | - | NPPES |
| 115420 | Other | UNISON | |
| 000121504 | Other | HIGHMARK | |
| P002109 | Other | GATEWAY | |
| 0017108050003 | Medicaid | PA | |
| 207489 | Other | UPMC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD069984 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medexpress Urgent Care Pc - Pennsylvania | 8224181482 | 234 |
News Archive
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.
University Hospitals Case Medical Center is the first surgical site for a Phase 2b clinical trial study to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.
The Washington Post leads the paper today with a report that "a new Washington Post-ABC poll shows that support for a government-run health-care plan to compete with private insurers has rebounded from its summertime lows and wins clear majority support from the public."
A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinal degeneration in rats with a type of inherited blindness, according to a Cedars-Sinai study.
The cover for issue 12 of Oncotarget features Figure 11, "Global analyses of the RNA-Seq data of LNCaP empty vector and LNCaP cells overexpressing hPCL3S (Clone 12)" by Abdelfettah, et al.
› Verified 6 days ago
| Entity Name | Washington Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1922077205 PECOS PAC ID: 0446159313 Enrollment ID: O20050420000827 |
News Archive
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.
University Hospitals Case Medical Center is the first surgical site for a Phase 2b clinical trial study to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.
The Washington Post leads the paper today with a report that "a new Washington Post-ABC poll shows that support for a government-run health-care plan to compete with private insurers has rebounded from its summertime lows and wins clear majority support from the public."
A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinal degeneration in rats with a type of inherited blindness, according to a Cedars-Sinai study.
The cover for issue 12 of Oncotarget features Figure 11, "Global analyses of the RNA-Seq data of LNCaP empty vector and LNCaP cells overexpressing hPCL3S (Clone 12)" by Abdelfettah, et al.
› Verified 6 days ago
| Entity Name | Medexpress Urgent Care Pc - Pennsylvania |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982839031 PECOS PAC ID: 8224181482 Enrollment ID: O20090805000511 |
News Archive
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.
University Hospitals Case Medical Center is the first surgical site for a Phase 2b clinical trial study to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.
The Washington Post leads the paper today with a report that "a new Washington Post-ABC poll shows that support for a government-run health-care plan to compete with private insurers has rebounded from its summertime lows and wins clear majority support from the public."
A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinal degeneration in rats with a type of inherited blindness, according to a Cedars-Sinai study.
The cover for issue 12 of Oncotarget features Figure 11, "Global analyses of the RNA-Seq data of LNCaP empty vector and LNCaP cells overexpressing hPCL3S (Clone 12)" by Abdelfettah, et al.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald J Faith, MD 95 Leonard Ave, Bldg 2, Washington, PA 15301-3368 Ph: (724) 223-3100 | Donald J Faith, MD 3415 Millers Run Rd, Cecil, PA 15321-1403 Ph: (724) 873-7414 |
News Archive
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.
University Hospitals Case Medical Center is the first surgical site for a Phase 2b clinical trial study to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.
The Washington Post leads the paper today with a report that "a new Washington Post-ABC poll shows that support for a government-run health-care plan to compete with private insurers has rebounded from its summertime lows and wins clear majority support from the public."
A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinal degeneration in rats with a type of inherited blindness, according to a Cedars-Sinai study.
The cover for issue 12 of Oncotarget features Figure 11, "Global analyses of the RNA-Seq data of LNCaP empty vector and LNCaP cells overexpressing hPCL3S (Clone 12)" by Abdelfettah, et al.
› Verified 6 days ago
Mylaina Lyn Sherwood, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3415 Millers Run Rd, Cecil, PA 15321 Phone: 724-873-7414 Fax: 724-873-7421 | |
Sarah Carolyn Duncan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3415 Millers Run Rd, Cecil, PA 15321 Phone: 724-873-7414 Fax: 724-873-7421 |